Neumora Therapeutics, Inc.

For the period ended Jun 30, 2025. Filed Aug 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 6, 2025

NMRA$0.47-4.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(unaudited, in thousands, except per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,
	2025	2024	2025	2024
Operating expenses:
Research and development	$38,724	$48,628	$90,875	$94,385
General and administrative	15,316	15,194	34,101	29,511
Total operating expenses	54,040	63,822	124,976	123,896
Loss from operations	(54,040)	(63,822)	(124,976)	(123,896)
Other income (expense):
Interest income, net	1,814	5,271	4,888	11,636
Other expense, net	(480)	(24)	(505)	(36)
Total other income	1,334	5,247	4,383	11,600
Net loss before income taxes	(52,706)	(58,575)	(120,593)	(112,296)
Provision for income taxes	25	125	130	125
Net loss	(52,731)	(58,700)	(120,723)	(112,421)
Other comprehensive loss:
Unrealized loss on marketable securities	(12)	(39)	(77)	(111)
Comprehensive loss	$(52,743)	$(58,739)	$(120,800)	$(112,532)
Net loss per share, basic and diluted	$(0.33)	$(0.37)	$(0.75)	$(0.71)
Weighted-average shares outstanding, basic and diluted	161,691	158,984	161,572	158,464

The accompanying notes are an integral part of these condensed consolidated financial statements

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.